 |
市場調查報告書
商品編碼
1460127
椎體壓迫骨折器械市場- 按產品類型（球囊椎體後凸成形術、椎體成形術）、手術（微創脊椎手術、開放性脊椎手術）、最終用途（醫院、ASC、創傷中心） -全球預測2024 - 2032Vertebral Compression Fracture Devices Market - By Product Type (Balloon Kyphoplasty, Vertebroplasty), Surgery (Minimally Invasive Spine Surgery, Open Spine Surgery), End-use (Hospital, ASCs, Trauma Centers) - Global Forecast 2024 - 2032 |
||||||
在微創手術的興起和技術進步的推動下，椎骨壓縮骨折器材市場規模從 2024 年到 2032 年將以 7.8% 的複合CAGR成長。
椎體成形術和椎體後凸成形術等微創手術可減少椎體骨折患者的術後疼痛、恢復更快並縮短住院時間。這一趨勢推動了對創新椎體壓迫骨折 (VCF) 設備的需求，因為它們專為精確、安全和有效的治療而設計。高黏度骨水泥、先進影像方式和導航工具等技術進步也提高了 VCF 手術的有效性和安全性。例如，2023 年 11 月，醫學影像領域的知名領導者 ImageBiopsy Lab 推出了 IB Lab FLAMINGO，這是一種深度學習電腦模型，可在 CT 掃描中檢測椎骨壓迫性骨折。隨著醫療保健提供者採用這些先進設備來改善患者的治療效果，市場有望獲得成長動力。
椎體壓迫骨折器械產業分為產品類型、手術、最終用途和地區。
就產品類型而言，預計 2024 年至 2032 年椎體成形術領域的市場規模複合CAGR為 6.9%。椎體成形術是一種微創手術，涉及將骨水泥注射到骨折的椎骨以穩定和減輕疼痛。此外，技術進步正在為高黏度骨水泥和導航工具的開發讓路。骨質疏鬆症相關椎體骨折盛行率的上升以及擴大採用椎體成形術來治療疼痛將進一步推動該細分市場的成長。
就最終用途而言，門診手術中心(ASC) 領域的椎體壓縮骨折器械行業將在2023 年產生可觀的收入，並預計在2032 年之前實現8.6% 的成長率。ASC 為傳統醫院提供高效且經濟高效的替代方案VCF 治療的設置。此外，ASC 對微創技術和快速恢復優勢的關注與 VCF 治療不斷成長的需求一致。由於 ASC 的便利性、較短的等待時間以及包括椎體成形術和椎體後凸成形術在內的門診手術的可用性，患者對 ASC 的偏好不斷增加，這將促進該細分市場的成長
從地區來看，亞太地區椎體壓縮骨折器械產業在2023 年擁有可觀的收入，並且在人口老化不斷擴大的推動下，到2032 年將呈現8.2% 的成長率，而老齡化人口更容易發生骨質疏鬆相關骨折。根據亞洲骨質疏鬆症協會聯合會的數據，50歲以上的新加坡女性中有三分之一患有骨質疏鬆症。此外，研究預測，新加坡因骨質疏鬆症導致的骨折總數將從 2017 年的 15,267 例增加到 2035 年的 24,104 例，在不到 20 年的時間裡激增 57.9%。人們對椎體壓迫性骨折微創手術的認知不斷提高，以及醫療保健支出的增加，將增強該地區的產業前景。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 骨質疏鬆症盛行率增加
- 椎體壓迫骨折裝置的技術進步
- 隨著脊椎相關疾病患者數量的增加，認知程度不斷提高
- 產業陷阱與挑戰
- 設備成本高
- 與術後併發症相關的風險
- 成長動力
- 成長潛力分析
- 監管環境
- 技術景觀
- 波特的分析
- PESTEL分析
- 未來市場趨勢
第 4 章：競爭格局
- 介紹
- 公司矩陣分析
- 公司市佔率分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按產品類型，2018 年 - 2032 年
- 主要趨勢
- 球囊椎體後凸成形術
- 椎體成形術
第 6 章：市場估計與預測：按手術分類，2018 - 2032 年
- 主要趨勢
- 微創脊椎手術
- 開放性脊椎手術
第 7 章：市場估計與預測：按最終用途，2018 - 2032 年
- 主要趨勢
- 醫院
- 門診手術中心
- 創傷中心
- 其他最終用戶
第 8 章：市場估計與預測：按地區分類，2018 年 - 2032 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 9 章：公司簡介
- Becton, Dickinson and Company
- Boston Scientific Corporation
- IZI Medical Products
- Johnson & Johnson (DePuy Synthes)
- Medtronic Plc
- Merit Medical Systems Inc
- Spine Wave, Inc
- Spirit Spine Holdings Corporation Inc.
- Stryker Corporation
- Zimmer Biomet Holdings, Inc.
Vertebral Compression Fracture Devices Market size is poised to expand at 7.8% CAGR from 2024 to 2032 driven by the rise in minimally invasive surgeries and technological advancements.
Minimally invasive procedures, such as vertebroplasty and kyphoplasty offer less post-operative pain, quicker recovery, and reduced hospital stays for patients with vertebral fractures. This trend is driving the demand for innovative vertebral compression fracture (VCF) devices as they are designed for precise, safe, and effective treatment. Technological advancements, such as high-viscosity bone cement, advanced imaging modalities, and navigational tools are also enhancing the efficacy and safety of VCF procedures. For instance, in November 2023, ImageBiopsy Lab, an established leader in medical imaging, launched IB Lab FLAMINGO, a deep-learning computer model that can detect vertebral compression fractures in CT scans. With healthcare providers adopting these advanced devices to improve patient outcomes, the market is poised to gain momentum.
The vertebral compression fracture devices industry is segmented into product type, surgery, end-use, and region.
With respect to product type, the market size from the vertebroplasty segment is projected to witness 6.9% CAGR from 2024-2032. Vertebroplasty is a minimally invasive procedure that involves the injection of bone cement into fractured vertebrae to stabilize and alleviate pain. Furthermore, technological advancements are making way for the development of high-viscosity bone cement and navigational tools. The rising prevalence of osteoporosis-related vertebral fractures and the increasing adoption of vertebroplasty for pain management will further propel the segment growth.
In terms of end-use, the vertebral compression fracture devices industry from the ambulatory surgical centers (ASCs) segment generated substantial revenue in 2023 and is poised to record 8.6% growth rate through 2032. ASCs offer efficient and cost-effective alternatives to traditional hospital settings for VCF treatments.. Additionally, the focus of ASCs' on minimally invasive techniques and rapid recovery benefits aligns with the rising demand for VCF treatments. The increasing patient preference for ASCs due to their convenience, shorter wait times, and availability of outpatient procedures including vertebroplasty and kyphoplasty will boost segment growth
Regionally, the Asia Pacific vertebral compression fracture devices industry held a sizable revenue in 2023 and is set to exhibit 8.2% growth rate through 2032 driven by the expanding aging population, which is more susceptible to osteoporosis-related fractures. According to the Asian Federation of Osteoporosis Societies, one-third of Singaporean women aged above 50 years have osteoporosis. Furthermore, studies predict that the overall number of fractures caused by osteoporosis in Singapore will rise from 15,267 in 2017 to 24,104 in 2035, representing a 57.9% spike in less than 20 years. Rising awareness about minimally invasive procedures for vertebral compression fractures, and increasing healthcare expenditure will augment the regional industry outlook.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definition
- 1.2 Base estimates & calculations
- 1.3 Data collection
- 1.4 Forecast parameters
- 1.5 Data validation
- 1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
- 1.6.2.1 Paid sources
- 1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of osteoporosis
- 3.2.1.2 Technological advancements vertebral compression fracture devices
- 3.2.1.3 Rising awareness levels coupled with growing patient population of spine related disorders
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of devices
- 3.2.2.2 Risk associated with post-surgical complications
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutes
- 3.6.5 Industry rivalry
- 3.7 PESTEL analysis
- 3.8 Future market trends
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Balloon kyphoplasty
- 5.3 Vertebroplasty
Chapter 6 Market Estimates and Forecast, By Surgery, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Minimally invasive spine surgery
- 6.3 Open spine surgery
Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Ambulatory surgical centers
- 7.4 Trauma centers
- 7.5 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Becton, Dickinson and Company
- 9.2 Boston Scientific Corporation
- 9.3 IZI Medical Products
- 9.4 Johnson & Johnson (DePuy Synthes)
- 9.5 Medtronic Plc
- 9.6 Merit Medical Systems Inc
- 9.7 Spine Wave, Inc
- 9.8 Spirit Spine Holdings Corporation Inc.
- 9.9 Stryker Corporation
- 9.10 Zimmer Biomet Holdings, Inc.
